ACCESS! 2020 IS CANCELED. CLICK TO LEARN MORE.

As Administrator of CMS, Seema Verma oversees one of our nation’s largest federal agencies, that is responsible for health care programs for more than 130 million Americans. With the government as the largest customer of the pharmaceutical industry - this is a unique opportunity to hear directly from the decision-maker whose thinking shapes our bottom line. Administrator Verma has set a bold agenda that emphasizes delivering value to patients, while also stressing greater quality and safety in America’s health care. Knowing what CMS is planning is essential to your own business strategy. We are fortunate to have Seema Verma join us at Access! 2020 to share her own story, her work as part of the Trump administration and her insights into the challenges and opportunities facing our industry. : Featured

Stephen M. Hahn, M.D.

Dr. Stephen M. Hahn was sworn in as the 24th Commissioner of Food and Drugs on December 17, 2019. Dr. Hahn is a physician, scientist and health care leader with an extensive background in patient care, academic research and executive leadership.

Dr. Hahn is a dedicated clinician, having trained in both medical oncology and radiation oncology. In his previous leadership roles, he has always carefully balanced executive management with clinical time to continue to serve oncology patients, his true passion. He specializes in treating both lung cancer and sarcoma.

Throughout his oncology career, Dr. Hahn maintained a keen interest in research, authoring more than 220 peer-reviewed original research articles. His research focuses on the molecular causes of the tumor microenvironment, particularly the study of chemical signals that go awry (known as aberrant signal transduction pathways), and the evaluation of proton therapy as a means of improving the effectiveness of radiation therapy. His experience in medical product development and clinical trials spans drugs, biologics, medical devices, and diagnostics.

Prior to joining the FDA, Dr. Hahn served as the chief medical executive (CME) at The University of Texas MD Anderson Cancer Center, a facility that cares for more than 140,000 patients a year. He has proven executive leadership that spans research, development, clinical trials, patient care, health system management and education. In his role as CME, he was responsible for day-to-day management of the institution, including business, clinical and faculty matters. Under his purview was one of the largest clinical trial groups in the country. Dr. Hahn joined MD Anderson in 2015 as Division Head, Department Chair and Professor of Radiation Oncology. Before joining MD Anderson, he served as chair of the Radiation Oncology department at the University of Pennsylvania’s Perelman School of Medicine from 2005 to 2014.

Dr. Hahn earned the rank of Commander in the U.S. Public Health Service Commissioned Corps while at the National Institute of Health’s National Cancer Institute, where he also completed a fellowship in medical oncology and a residency in radiation oncology. He also a completed residency in internal medicine at University of California, San Francisco. He graduated from the Lewis Katz School of Medicine at Temple University in Pennsylvania and received his bachelor’s in biology from Rice University in Texas.

Seema Verma

As Administrator of CMS, Seema Verma oversees one of our nation’s largest federal agencies, that is responsible for health care programs for more than 130 million Americans. With the government as the largest customer of the pharmaceutical industry – this is a unique opportunity to hear directly from the decision-maker whose thinking shapes our bottom line.

Administrator Verma has set a bold agenda that emphasizes delivering value to patients, while also stressing greater quality and safety in America’s health care. Knowing what CMS is planning is essential to your own business strategy.

We are fortunate to have Seema Verma join us at Access! 2020 to share her own story, her work as part of the Trump administration and her insights into the challenges and opportunities facing our industry.

Janet Woodcock, M.D.

Janet Woodcock is Director of the Center for Drug Evaluation and Research (CDER), at the Food and Drug Administration (FDA).

In 2015, Dr. Woodcock also assumed the role of Acting Director of CDER’s newly formed Office of Pharmaceutical Quality, (OPQ).   Dr. Woodcock first joined CDER in 1994. For three years, from 2005 until 2008, she served FDA’s Commissioner, holding several positions, including as Deputy Commissioner and Chief Medical Officer, Deputy Commissioner for Operations, and Chief Operating Officer.

Her responsibilities involved oversight of various aspects of scientific and medical regulatory operations. Before joining CDER, Dr. Woodcock served as Director, Office of Therapeutics Research and Review, and Acting Deputy Director in FDA’s Center for Biologics Evaluation and Research.

Dr. Woodcock received her M.D. from Northwestern Medical School and completed further training and held teaching appointments at the Pennsylvania State University and the University of California in San Francisco. She joined FDA in 1986.